QYUNS-B: QX004N enters Phase III clinical trial and receives payment from HANSOH PHARMA
I'm PortAI, I can summarize articles.
QYUNS-B announced that its interleukin 23p19 inhibitor QX004N has entered Phase III clinical trials and has signed an exclusive licensing agreement with HANSOH PHARMA, covering research and development, production, and commercialization in mainland China, Taiwan, Hong Kong, and Macau. The company has received milestone and other payments of RMB 58 million from HANSOH PHARMA
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments